Thymidylate synthase

From Proteopedia

Thymidylate synthase (TS) is an important enzyme in one-carbon metabolism. TS catalyzes the transfer of a methyl group and a hydride from 5,10-methylenetetrahydrofolate to 2-deoxyuridine-5'-monophosphate, resulting in the formation of thymidine 5'-monophosphate and dihydrofolate. This is the only de novo source of dTMP (a precursor to Thymine) in humans. ^[1]

2-deoxyuridine-5'-monophosphate(dUMP) + 5,10-methylenetetrahydrofolate(CH₂H₄F) ⇌ thymidine 5'-monophosphate(dTMP) + Dihydrofolate(H₂F)

The above image depicts the overall reaction catalyzed by TS. The section of the molecules contained in boxes highlights the differences between the substrates and products as a result of this reaction.

Function

Thymidylate synthase catalyzes the methylation of dUMP to dTMP using 5,10-methylenetetrahydrofolate as a cofactor. TS is essential for DNA replication and repair^[2]. In protozoa, dihydrofolate reductase (DHFR) and TS are expressed as a bifunctional monomeric enzyme (DHFR-TS) with the DHFR entity at the N terminal. DHFR and TS catalyze consecutive reactions in the dTMP biosynthesis. There are two different types of TS – ThyA and ThyX. The types differ in their activity and structure. The TS ThyX are flavin-dependent enzymes.

Relevance

One of the nucleobase of DNA, cytosine, spontaneously deaminates to form uracil, changing the encoded message. Different from RNA, DNA does not contain uracil but instead contains the methylated form thymine, avoiding missense mutations. The DNA repair protein Uracil DNA glycosylase will recognize uracil as damaged DNA, removing it and re-establishing the original message^[3]. Because thymine contains an additional methyl group, it is distinguishable from uracil, and is not removed through DNA repair. Thymidylate synthase helps to turn the abundant uridine (containing the nucleobase uracil) into deoxythymidine (containing the nucleobase thymine) in preparation for DNA synthesis prior to cell division. Thus, thymidylate synthase plays a role in making DNA a more reliable long-term storage of genetic information compared to RNA.

TS inhibition at its folate-binding site is used in anticancer therapeutic drugs. DHFR-TS inhibitors are potential drug targets against parasite-transferred diseases. TS exhibits oncogene-like activity.^[4]

Mechanism

There are two potential pathways that the mechanism for TS could operate by, however it is unclear which pathway the mechanism follows. In both pathways, the substrates form a covalent ternary complex with the enzyme. This complex facilitates the transfer of the methyl group from CH₂H₄F to dUMP and is followed by a hydride transfer from the folate substrate to the dMP substrate. During the A pathway (highlighted in red), the intermediate complex remains covalently bound to the enzyme. The B pathway (highlighted in blue) involves the decoupling of the intermediate from the active site cysteine.

spinqualitylabelsall models Thymidylate synthase complex with dUMP (PDB entry 1tsv) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Structure and ligand binding TS forms a homodimer consisting of two domains (reload ). Their can each bind the substrate dUMP[5]. The sketch below shows some of the ionic and hydrogen bonding interactions between the protein and the substrate, most of which are also shown in the 3D scene. You can measure distances and angles after turning off the spinning (for detailed instructions, see viewing guide, [1]). Maley et al. show that E.coli TS uses a half-the-sites mechanism when catalyzing its reaction[6]. One of the two active sites catalyzes the reaction while the other remains inactive. The way the two domains communicate with each other to coordinate this is still unknown. To distinguish between path A (in which cysteine remains covalently bound during methyl and hydride transfer) and path B (in which cysteine shows two separated nucleophilic attacks on carbon C6) in the mechanistic hypotheses depicted above, Kholodar et al co-crystallized the enzyme with an analog of the .[1] While the natural intermediate contains a carbonyl oxygen (circled in yellow), the cocrystallized intermediate has an amine () in that position instead. In the crystal structure determination, one active site binds to the bisubstrate analog (as shown) while the other active site binds to the products. This fits with the half-the-sites mechanism mentioned above. The active site cysteine initially covalently binds to carbon 6 of the dUMP-ring. As seen here in the analog of intermediate conformations, it is not covalently bound here. The active site is disordered in the structure, showing . One conformation shows the active site cysteine 4.21 Angstroms away from the C6 carbon of the dMP ring and the other 3.84 Angstroms away from the C6 carbon of the dMP ring. Inhibition Methotrexate, a competitive inhibitor competes with folate substrate to of TS and inhibits the conversion of CH2H4F to H2F. This inhibition stops the conversion of products to reactants, stopping cellular reproduction. The image below shows folic acid on the top and the inhibitor methotrexate on the bottom. Compared the the substrate CH2H4F to H2F, methotrexate has an additional amino group, lacks four hydrogens in the ring (i.e. has more double bonds), and is N-methylated in a different position. Due to its role in cell division, thymidylate synthase has become a popular target for anticancer drugs. Indirect inhibition of thymidylate synthase by the drug 5-fluorouracil (5-FU) is one of the most used inhibitors for study of TS function. This drug indirectly inhibits TS as it it eventually converted to FdUMP, which forms a covalent complex with both the active site cysteine and CH2H4F. Inhibition of TS halts the production of dTMP and, indirectly, 2'-deoxythymidine-5'-triphosphate (dTTP). Both dTMP and dTTP are essential building blocks for DNA synthesis and their absence halts the ability of cells to replicate their genetic information. This is especially effective in cancer cells that rapidly divide and require large amounts of dTMP and dTTP. [7]

3D structures of thymidylate synthase

Thymidylate synthase 3D structures

Acknowledgements

Michael O'Shaughnessy would like to thank Dr. Karsten Theis as well his classmates from Biochemistry II (Shaylie Albright, Anna Postnikova, and Kia Yang) from the Spring 2022 semester for their contributions to this page, and would also like to thank Dr. Craig Martin from University of Massachusetts Amherst for his feedback on this page.

References

1. ↑ ^{1.0 1.1} Kholodar SA, Finer-Moore JS, Swiderek K, Arafet K, Moliner V, Stroud RM, Kohen A. Caught in Action: X-ray Structure of Thymidylate Synthase with Noncovalent Intermediate Analog. Biochemistry. 2021 Apr 8. doi: 10.1021/acs.biochem.1c00063. PMID:33829766 doi:http://dx.doi.org/10.1021/acs.biochem.1c00063
2. ↑ Kaneda S, Nalbantoglu J, Takeishi K, Shimizu K, Gotoh O, Seno T, Ayusawa D. Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem. 1990 Nov 25;265(33):20277-84. PMID:2243092
3. ↑ Krokan HE, Drablos F, Slupphaug G. Uracil in DNA--occurrence, consequences and repair. Oncogene. 2002 Dec 16;21(58):8935-48. doi: 10.1038/sj.onc.1205996. PMID:12483510 doi:http://dx.doi.org/10.1038/sj.onc.1205996
4. ↑ Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ, Zajac-Kaye M. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell. 2004 Apr;5(4):341-51. PMID:15093541
5. ↑ Finer-Moore JS, Fauman EB, Morse RJ, Santi DV, Stroud RM. Contribution of a salt bridge to binding affinity and dUMP orientation to catalytic rate: mutation of a substrate-binding arginine in thymidylate synthase. Protein Eng. 1996 Jan;9(1):69-75. PMID:9053905
6. ↑ Maley F, Pedersen-Lane J, Changchien L. Complete restoration of activity to inactive mutants of Escherichia coli thymidylate synthase: evidence that E. coli thymidylate synthase is a half-the-sites activity enzyme. Biochemistry. 1995 Feb 7;34(5):1469-74. doi: 10.1021/bi00005a001. PMID:7849005 doi:http://dx.doi.org/10.1021/bi00005a001
7. ↑ Costi MP, Ferrari S, Venturelli A, Calo S, Tondi D, Barlocco D. Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem. 2005;12(19):2241-58. doi: 10.2174/0929867054864868. PMID:16178783 doi:http://dx.doi.org/10.2174/0929867054864868